Results 8,221-8,240 of 12,738 for speaker:Louise O'Reilly

Written Answers — Department of Health: Mental Health Services (6 Mar 2019)

Louise O'Reilly: 201. To ask the Minister for Health the reason family members with residents in a facility (details supplied) are being invited by the HSE to meet with an independent psychiatrist; the intentions behind such meetings; the options being considered in view of these meetings; and if he will make a statement on the matter. [11105/19]

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: I thank the representatives for coming in and for their presentation. According to the opening statement, the current research and development model is unsuitable and has the potential to bankrupt to healthcare system while failing to advance public health. It is very hard to disagree with that. Our questions are to try and scope out the potential for moving away from where we are. I...

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: On good practice, can the witnesses point to anywhere that has got it right and from which we could copy?

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: We need to get to the point where, regardless of whatever it is we put in, we have some influence over the direction the research takes in the first instance and over the eventual cost. The Drugs for Neglected Diseases Initiative has been mentioned. I understand it has yielded some decent results but does it have the potential to be scaled up?

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: Is there anything the Government could do to ensure the clinical trial process is more transparent? Of all the clinical trial results that are produced here, do we know how many are publicly funded? Are they all publicly funded? Are they all published? I am conscious that there is an effective subsidy in place, in some instances, for these clinical trials. That does not necessarily...

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: Is there anything we can do to improve on it?

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: Therefore the industry is effectively policing itself in this regard.

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: I do not know how true it is but we have all read that most global pharmaceutical companies will spend more on advertising than on research and development. If that is the case, it undermines much of the discourse on the subject. These debates get very heated because we are talking about seriously ill people and, in some instances, seriously ill children. The retort from the pharmaceutical...

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: Do the witnesses imagine that it goes on advertising?

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: Is a good chunk of the money spent on advertising?

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: I thank the witnesses.

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: It is interesting that Dr. Harkin would hold out the hope for BeNeLuxA because it is important that it would deliver. Outside our roles as Deputies or Senators, is there anything practical that we as a committee can do in response to the issues he raised? We may not all agree on everything and there are people here who have a much more benign view of pharmaceutical companies than I do but...

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: Or if we could attach a proviso that further public investment is on the basis of a return for public health. That should not be a wild or strange concept but perhaps it is. We should consider that.

Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)

Louise O'Reilly: It is hard to define exactly what the investment is because if the laboratory has been built and staffed and a company sponsors a bursary of €30,000 or €40,000 that investment is on paper but the State has invested in the bricks and mortar, the personnel, the person who comes to clean the place, and the lights. It is difficult to do but it is not impossible and it is not...

Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)

Louise O'Reilly: I move amendment No. 23: In page 12, line 24, to delete “75C. An authorised officer” and substitute “75D. An authorised officer”.

Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)

Louise O'Reilly: I move amendment No. 24: In page 12, line 36, to delete “75D. Every order” and substitute “75E. Every order”.

Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)

Louise O'Reilly: The Minister says he agrees in principle with what I am saying because, clearly, it makes sense. However, he said that at the opportune time he would provide the report. I would be most grateful if he could firm up that proposal. We are saying within a year because, in the event that we have to enact this legislation, we are going to be in uncharted territory. It would be no harm, after...

Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019: Committee Stage (5 Mar 2019)

Louise O'Reilly: I move amendment No. 22:In page 12, between lines 22 and 23, to insert the following:"Review of the effectiveness of health services 75C.The Minister shall publish a review into the effectiveness of the health services covered under section 75A and 75B of this Act one year after the United Kingdom has left the European Union.". This is a straightforward amendment. Obviously, none of us...

Written Answers — Department of Public Expenditure and Reform: Information and Communications Technology (5 Mar 2019)

Louise O'Reilly: 155. To ask the Minister for Public Expenditure and Reform if Ireland has set up its electronic data exchange system known as e-cohesion; and if not, the reason. [10535/19]

Written Answers — Department of Public Expenditure and Reform: Information and Communications Technology (5 Mar 2019)

Louise O'Reilly: 156. To ask the Minister for Public Expenditure and Reform if Ireland has implemented a national information technology system to meet the 2014-2020 European Structural and Investment Funds requirements; and if not, the amount of funding which has either been lost or been unable to be drawn down each year due to this in tabular form. [10537/19]